A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme

David K Lau, Miles C Andrews, Natalie Turner, Arun Azad, Ian Davis, Jonathan Cebon

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)=2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16 ) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.
Original languageEnglish
Pages (from-to)144 - 149
Number of pages6
JournalMelanoma Research
Volume24
Issue number2
DOIs
Publication statusPublished - 2014

Cite this

Lau, David K ; Andrews, Miles C ; Turner, Natalie ; Azad, Arun ; Davis, Ian ; Cebon, Jonathan. / A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. In: Melanoma Research. 2014 ; Vol. 24, No. 2. pp. 144 - 149.
@article{cbb587d3e47d492cbae271d3185e9fa7,
title = "A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme",
abstract = "We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)=2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16 ) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.",
author = "Lau, {David K} and Andrews, {Miles C} and Natalie Turner and Arun Azad and Ian Davis and Jonathan Cebon",
year = "2014",
doi = "10.1097/CMR.0000000000000036",
language = "English",
volume = "24",
pages = "144 -- 149",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme. / Lau, David K; Andrews, Miles C; Turner, Natalie; Azad, Arun; Davis, Ian; Cebon, Jonathan.

In: Melanoma Research, Vol. 24, No. 2, 2014, p. 144 - 149.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme

AU - Lau, David K

AU - Andrews, Miles C

AU - Turner, Natalie

AU - Azad, Arun

AU - Davis, Ian

AU - Cebon, Jonathan

PY - 2014

Y1 - 2014

N2 - We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)=2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16 ) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.

AB - We studied the efficacy, tolerability and clinical courses of dabrafenib in patients with metastatic melanoma who were ineligible for enrolment into a clinical trial. Between July 2011 and May 2013, patients with unresectable stage III or stage IV, V600-mutated metastatic melanoma who were not eligible for inclusion into clinical trials were offered treatment with dabrafenib through a named patient programme. Routine efficacy and toxicity data were collected throughout treatment and studied retrospectively. The endpoints were progression-free survival (PFS), overall survival and best overall response. Thirty-one patients commenced dabrafenib therapy including six individuals who had progressed on a prior BRAF-inhibitor treatment. The majority of patients had cerebral metastases (n=17) and/or a poor performance status [Eastern Cooperative Oncology Group (ECOG)=2, n=11]. Median overall survival was 5.6 months (range 0.1-22 months). Median PFS was 3.3 months (range 0.1-21) and was similar despite performance status. One patient had a complete response and eight showed partial responses to treatment. Patients with cerebral metastases (n=17) had a median PFS of 4.6 months. Five patients (16 ) had dose-limiting toxicities. Despite several poor prognostic features, dabrafenib is a safe and effective treatment in the community setting, with occasional impressive outcomes.

UR - http://www.ncbi.nlm.nih.gov/pubmed/24463460

U2 - 10.1097/CMR.0000000000000036

DO - 10.1097/CMR.0000000000000036

M3 - Article

VL - 24

SP - 144

EP - 149

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 2

ER -